Prevalence of genotypic resistance to nucleoside analogues, nonnucleoside analogues, and protease inhibitors in HIV-infected persons in Athens, Greece.
PMID: 18275347
2008
AIDS research and human retroviruses
Abstract: L90M (26.5%) was among the most frequently observed single key protease mutations in our series, although variables of V82 and I54 amino acid substitutions were more frequent.
Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.
Abstract: The most frequent mutations selected under therapy (compared to HIV-2 ROD) were V71I, L90M and I89V within PR.
Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir.
PMID: 18390885
2008
The Journal of antimicrobial chemotherapy
Abstract: Two fosamprenavir/ritonavir mutation scores were constructed: score A (L10F/I/V + L33F + M36I + I54L/M/V/A/T/S + I62V + V82A/F/C/G + I84V + L90M) was based only on mutations associated with a worse VR, whereas score B (L10FIV + L33F + M36I + I54L/M/V/A/T/S + A71V - V77I - N88S + L90M) also took into account favourable mutations.
Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir.
Introduction: Previously, the crystal structure of the double mutant G48V/L90M with saquinavir was analyzed, and we reported the structure of the PRI50V mutant with darunavir.
Result: Analysis of the available structures of these flap mutants with saquinavir or darunavir showed the largest changes in PRG48V/L90M-SQV and PRI50V-DRV relative to the corresponding wild type complexes.
Result: However, the crystal structure of the double mutant PRG48V/L90M with SQV (1FB7) shows that saquinavir moves to accommodate the bigger side chain of Val48, giving rise to weaker interactions than in the PR-SQV structure.
Result: The hydrogen bond between Gly48 and saquinavir was a
Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.
Abstract: Minority-resistant variants were searched by allele-specific PCR for the mutations K103N and M184V in reverse transcriptase and L90M in protease.
Analysis of near full-length genomic sequences of drug-resistant HIV-1 spreading among therapy-naive individuals in Nagoya, Japan: amino acid mutations associated with viral replication activity.
PMID: 18620491
2008
AIDS research and human retroviruses
Abstract: Genomes comprised seven protease inhibitor (PI)-resistant viruses possessing an M46I (n = 6) or L90M mutation (n = 1) and five non-nucleoside reverse transcriptase inhibitor-resistant viruses possessing a K103N mutation.
Prevalence of drug resistance and associated mutations in HIV-positive Puerto Ricans: sex variations.
Abstract: Eight validated real-time PCR-based assays were used to test for minority drug resistance mutations (protease L90M and reverse transcriptase M41L, K70R, K103N, Y181C, M184V, and T215F/Y) above naturally occurring frequencies.
Result: Four samples (2% overall) had the following mutations to two drug classes: L90M+M184V, L90M+Y181C, Y181C+T215F, and L90M+M41L+
HIV drug resistance pattern among HAART-exposed patients with suboptimal virological response in Ouagadougou, Burkina Faso.
PMID: 18667925
2008
Journal of acquired immune deficiency syndromes (1999)
Abstract: Some resistance mutations, notably D67N/G, K70R and L210W (thymidine analogue mutations-TAMs); K101E, V179E in RT, 154V, V82A/T/F and L90M in PR were significantly higher among CRF06_cpx than CRF02_AG strains (P < 0.05).
Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria.
PMID: 18788909
2008
AIDS research and human retroviruses
Abstract: The commonest resistance mutations resulted in the NRTI mutation M184V (42.1%) and the PI mutation L90M (24.1%).
HIV mutation literature information.
PMID: 
2008
AIDS research and human retroviruses
Browser Board
Co-occurred Entities
Filtrator
ViMRT